| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-06-10 | ExpreS2ion Biotechnologies (Denmark) Cancer Research UK’s London Research Institute (UK) | Drosophila Schneider-2 cell-based technology platform - ExpreS2 - for protein production | licensing |
Technology - Services | Licensing agreement | |
| 2013-06-10 | BiolineRx (Israel) CTTQ (China) | BL-8030 | hepatitis C | development |
Infectious diseases | Development agreement |
| 2013-06-08 | Bayer (Germany) CRS - Clinical Research Services Andernach GmbH (Germany) | R&D services for early clinical trials | collaboration clinical research |
Services contract | ||
| 2013-06-06 | Santhera Pharmaceuticals (Switzerland) National Institutes of Health (NIH) (USA) | idebenone | primary progressive Multiple Sclerosis (ppMS) | licensing |
Autoimmune diseases - Neurodegenerative diseases | Licensing agreement |
| 2013-06-06 | Flamel Technologies (France) undisclosed pharmaceutical company | undisclosed | undisclosed | development |
undisclosed | Development agreement |
| 2013-06-06 | Boehringer Ingelheim (Germany) Zhangjiang Biotech & Pharmaceutical Base Development Company (China) | cGMP biopharmaceuticals facility | collaboration |
Production agreement | ||
| 2013-06-05 | Meda (Sweden) Cipla (India) | Dymista® and future product development | allergic rhinitis | development |
Allergic diseases - Inflammatory diseases - Respiratory diseases | Development agreement |
| 2013-06-04 | Cancer Curie (France) Biolog-id (France) | RFID solutions | R&D |
Cancer - Oncology | R&D agreement | |
| 2013-06-04 | Theradiag (France) Cancer Institute of Montpellier (ICM) | microRNA-based theranostics tools for the screening and monitoring of colorectal cancer | colorectal cancer | R&D |
Cancer - Oncology | R&D agreement |
| 2013-06-04 | Mellitech (France) Janssen Pharmaceuticals - J&J (USA) | therapies targeting ZnT8 | metabolic diseases | R&D development commercialisation |
Metabolic diseases | |
| 2013-06-03 | Morphosys (Germany) GSK (UK) | MOR103 | rheumatoid arthritis, multiple sclerosis | development |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Neurodegenerative diseases | Development agreement |
| 2013-06-03 | OpGen (USA) Applied Maths (Belgium - USA) | advanced software tools for microbial genomics and molecular strain typing | development | Infectious diseases | ||
| 2013-05-31 | The Cell Therapy Catapult (UK) The Centre for Commercialization of Regenerative Medicine (CCRM) (Canada) | collaboration |
Regenerative medicine | Collaboration agreement | ||
| 2013-05-31 | Qiagen (The Netherlands) Columbia University (USA) | diagnostic test based on FGFR-TACC fusion genes | glioblastoma | licensing |
Cancer - Oncology | Licensing agreement |
| 2013-05-31 | Qiagen (The Netherlands) BC Cancer Agency (Canada) | EZH2 Y641 mutation biomarker | licensing |
Cancer - Oncology | Licensing agreement | |
| 2013-05-31 | BeiGene (China) Merck KGaA, Merck Serono (Germany) | BeiGene-283 (BRAF inhibitor) | licensing |
Cancer - Oncology | Milestone | |
| 2013-05-30 | AstraZeneca (UK) Neomed (Canada) | R&D |
R&D agreement | |||
| 2013-05-29 | VolitionRx (Singapore) Hvidovre Hospital (Denmark) | colorectal cancer clinical trials using NuQ® tests | colorectal cancer | clinical research |
Diagnostic - Cancer - Oncology | Clinical research agreement |
| 2013-05-28 | Thrombogenics (Belgium) Eleven Biotherapeutics (USA) | protein therapeutics | diabetic eye diseases such as diabetic macular edema | licensing |
Ophtalmological diseases | Licensing agreement |
| 2013-05-28 | Cobra Biologics (Sweden) Recopharma (Sweden) | programme of vector construction | R&D |
Technology - Services | R&D agreement |
